27. Oktober 2016

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

20. Juli 2016

Newest study on NIVOLUMAB mentioned by ASCO

19. Juni 2016

A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing. Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; SAKK. J Thorac Oncol. 2016 Jun 13. pii: S1556-0864(16)30507-X. doi: 10.1016/j.jtho.2016.05.032. [Epub ahead of print]

11. Juni 2016

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ. Breast Cancer Res Treat. 2016 Jun 8. [Epub ahead of print]

19. Mai 2016

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.Klazien Matter-Walstra, Matthias Schwenkglenks, Peter Brauchli, Dirk Klingbiel, Konstantin J. Dedes;J Clin Oncol 34, 2016 (suppl; abstr 567)

03. April 2016

Bevacizumab continuation versus treatment holidays after first-line chemotherapy with bevacizumab in patients with metastatic colorectal cancer: a health economic analysis of a randomised phase III trial (SAKK 41/06) Klazien Matter-Walstra, Matthias Schwenkglenks, Daniel Betticher, Roger von Moos, Daniel Dietrich, Daniela Baertschi, Dieter Koeberle, DOI: http://dx.doi.org/10.1016/j.clcc.2016.03.002 Publication stage: In Press Accepted Manuscript Published online: March 30 2016

21. Februar 2016

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09). Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Konzelmann I, Mousavi M, Clough-Gorr KM, Szucs T, Schwenkglenks M, Pestalozzi BC. Eur J Cancer Care (Engl). 2016 Feb 9. doi: 10.1111/ecc.12453. [Epub ahead of print]

27. Januar 2016

Is the EQ-5D suitable for use in oncology? An overview of literature and recent developments. Schwenkglenks M, Matter-Walstra K. Expert Rev Pharmacoecon Outcomes Res. 2016 Jan 25. [Epub ahead of print]

20. September 2015

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting. Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M. Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152. [Epub ahead of print]

18. Mai 2015

Resource use and costs of newly diagnosed cancer initial medical care Aleksandar Dagovic, Klazien Matter Walstra, Florian S. Gutzwiller, Natasa Djordjevic, Ana Rankovic, Gordana Djordjevic, Sanja Kocic, Dragan Vasiljevic, Predrag Canovic, Aleksandra Kovacevic, Djukic Aleksandar, Viktorija Dragojevic Simic, Mihajlo Jakovljevic, Matthias Schwenkglenks EUR. J. ONCOL.; Vol. 19, n. 3, pp. 166-184, 2014